Clinical significance of granulocytic sarcoma in adult patients with acute myeloid leukemia.

Cancer Science
Hiroaki ShimizuYoshihisa Nojima

Abstract

To investigate the clinical significance of granulocytic sarcoma (GS) in adults with acute myeloid leukemia (AML), 434 consecutive patients with AML were analyzed retrospectively. Forty-five patients (10.4%) with GS at diagnosis were younger (P < 0.001), presented with higher white blood cell counts (P = 0.03) and were more likely to conform to French-American-British M4 (P = 0.001) and M5 (P = 0.045) classifications than those without GS. In contrast, no significant difference in frequency of cytogenetic abnormalities was found between the GS and non-GS groups. Treatment outcomes in 260 patients (40 with GS) who underwent intensive chemotherapy, excluding patients with acute promyelocytic leukemia, were investigated. Complete remission rates did not differ significantly between the GS and non-GS groups (75.0% vs 79.1%; P = 0.192, respectively) or the 5-year overall survival (OS) rates (39.9% vs 38.7%; P = 0.749, respectively). However, the GS group had a significantly higher relapse rate than the non-GS group (74.2% vs 55.3%; P = 0.048) and a significantly lower 5-year disease-free survival rate (8.2% vs 25.7%, respectively; P = 0.005). When considered together with the results of multivariate analysis, which identified the pr...Continue Reading

References

Jun 1, 1992·Leukemia Research·Y IizukaT Horie
Nov 1, 1985·Scandinavian Journal of Haematology·M YamazakiT Akabane
Feb 1, 1984·British Journal of Haematology·D M SwirskyF G Hayhoe
Jul 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J C ByrdN A Dawson
Apr 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M S TallmanD Variakojis
Feb 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J C ByrdC D Bloomfield
Jun 1, 1997·The Journal of Obstetrics and Gynaecology Research·R KambleS Mittal
Dec 20, 2003·Orbit·Kasturi BhattacharjeeJyotirmay Biswas
Mar 11, 2004·British Journal of Haematology·Isao MiyoshiYuji Ohtsuki
Mar 19, 2004·Urology·S E EggenerT C Keeler
Mar 30, 2007·European Journal of Haematology·Jyoti KumarSeema Sen
Dec 18, 2007·Journal of Oral and Maxillofacial Surgery : Official Journal of the American Association of Oral and Maxillofacial Surgeons·Constantine KomisAlexander D Rapidis
Jul 9, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patrice ChevallierJean-Luc Harousseau

❮ Previous
Next ❯

Citations

Jul 5, 2013·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·A I BertaL Holbach
Mar 28, 2013·Archives of Pathology & Laboratory Medicine·Jane ZhouL Jeffrey Medeiros
Aug 10, 2013·The American Journal of the Medical Sciences·Jingsong HeHuang He
Jul 18, 2015·American Journal of Clinical Pathology·Carla S Wilson, L Jeffrey Medeiros
Apr 19, 2015·World Neurosurgery·Jacob R JosephDaniel A Orringer
Jul 28, 2016·Journal of Orthopaedic Science : Official Journal of the Japanese Orthopaedic Association·Osamu ObayashiKazuo Kaneko
Jan 11, 2020·Journal of Cancer Research and Clinical Oncology·Lu-Hong XuJian-Pei Fang
Oct 1, 2015·Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology·Tomoaki MiyagawaAtsushi Shinagawa
Mar 21, 2019·Case Reports in Hematology·Karuna DewanCourtney B Shires
Jan 30, 2021·International Journal of Hematology·Meng ShanDepei Wu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.